German benefit assessments are bad for innovation, says BI as Trajenta falls foul of the AMNOG
This article was originally published in Scrip
Executive Summary
Germany's early benefit assessment is blocking innovation and needs to be reformed, said members of Boehringer Ingelheim's board of managing directors at its annual press conference on 24 April. The firm says that it has been unable to launch its DPP4-inhibitor Trajenta (linagliptin) in Germany because of the system.